Understanding RAS/RAF: Novel Tools for RAS Pathway Drug Discovery
In this webinar, you will learn about novel tools to study the RAS pathway and its downstream components in relation to therapeutic drug discovery.
Summary
Are you interested in more innovative ways to study the RAS pathway? Are you currently designing small molecule therapeutics or implementing PROTAC strategies to target RAS components? Join us for an interactive webinar where Promega's research scientists share how our RAS/RAF technologies can simplify your research! We’ll start with a general overview of the technology, then break out into deep dive sessions that connected directly with R&D scientists and discussed our latest tools for your RAS research.
View these Breakout Sessions where you will learn about our growing portfolio of novel tools to study the RAS pathway and its downstream components, specifically in relation to therapeutic drug discovery.
- Protein:Protein Interaction - NanoBRET® and NanoBiT® technologies enable sensitive, reproducible detection of protein:protein interactions (PPI) in the natural cellular environment
- Target Engagement - NanoBRET® technology offers a sensitive, specific method to measure the interaction of small-molecule drugs with their target protein in live cells
- CRISPR Cell Lines - By using CRISPR/Cas9 gene editing to knocking a bioluminescent tag at endogenous loci of interest, proteins expressed by the native promoter can be studied using simple light output measurements
- Active RAS - Lumit® Phospho-ERK Immunoassay Cellular System is a no-wash bioluminescent immunoassay that analytes directly in cell lysates. The GTPase-Glo™ Assay analyzes the intrinsic activities of GTPase, GAP-stimulated GTPase, GAP and GEF
Speakers
Danette Daniels, PhD
Senior Research Scientist and Group Leader, Functional Proteomics
Promega Corporation
Danette Daniels received her B.A. from Columbia University, Ph.D. in Biophysics from Yale University, and completed a postdoctoral fellowship at Stanford University School of Medicine studying the biophysical and biochemical mechanisms of the Wnt signaling pathway. She has been at Promega Corporation for 15 years and is currently an R&D Group Leader of Functional Proteomics.
She leads a team developing technologies and performing research to understand dynamic intracellular interactions with the focus areas of epigenetics, transcription, targeted protein degradation, and small molecule drug discovery. She has been an author on ~40 peer-reviewed scientific publications, including original research articles, book chapters, and reviews.
Brock Binkowski, PhD
Senior Research Scientist
Promega Corporation
Brock Binkowski received his Ph.D. in Biochemistry and B.S. in Chemical Engineering from UW-Madison. After grad school, Brock worked as a post-doc at Promega where he helped to develop a platform of Fluc-based, intracellular biosensors (GloSensor Technology). He has been working at Promega since 2005, focusing on the development of luminescent assays. Brock and Chris Eggers work together on a team that has commercialized numerous assays related to NanoLuc Luciferase and NanoBiT Technology, such as NanoBiT PPI, Endurazine/Vivazine, NanoDLR, HiBiT Lytic, HiBiT Extracellular & HiBiT Blotting applications.
Matt Robers, PhD
Senior Research Scientist and Group Leader
Promega Corporation
Matthew Robers is a Senior Research Scientist and Group Leader at Promega Corporation. Prior to joining Promega, Matt was focused on pathway analysis in the cell-based assay group at Life Technologies. Matt has authored numerous peer-reviewed publications and published patents on the application of novel fluorescent and bioluminescent chemistries to measure intracellular protein dynamics.
The focus of Matt’s team at Promega is to apply new technologies to assess target engagement. Matt’s team has recently developed a biophysical technique for quantifying compound affinity and residence time at selected intracellular targets within intact cells.
James Vasta, PhD
Senior Research Scientist
Promega Corporation
At Promega, James is focused on the development and application of target engagement technologies to investigate drug-target interactions in live cells using NanoBRET. He is broadly interested in applying this technology, which has been successfully applied to at least 15 different target classes to date. Current areas of interest include wide spectrum live-cell kinase selectivity profiling, target engagement within the MAPK pathway including RAS, and E3 ligase target engagement as a tool for assessing permeability of PROTACs and cell penetrating peptides.
Prior to joining the team at Promega, James received his Ph.D. in Biochemistry from the University of Wisconsin-Madison, where he focused on developing inhibitors for the collagen prolyl 4-hydroxylases (CP4Hs), a group of enzymes implicated in myriad diseases including fibrosis, scurvy, and cancer. James has contributed to the discovery and patenting of a novel and selective human CP4H inhibitor, which is currently in pre-clinical investigations. Lastly, James received his Bachelor of Science in Biochemistry from Lafayette College in Easton, Pennsylvania, where he focused on using analytical methodologies to discover small-molecule biomarkers of parasitic infections.
Christopher Eggers, PhD
Senior Research Scientist and Group Leader
Promega Corporation
Chris Eggers received his Ph.D. in biochemistry and molecular biology from the University of California at San Francisco, where he studied molecular recognition through structure/function analysis and protein engineering. He then completed a postdoctoral fellowship at the University of California at San Diego, identifying the role of a PKA-scaffolding protein in membrane trafficking. Chris has been at Promega since 2011, working primarily to develop new luminescence-based biosensors and reporter assays.
Hicham Zegzouti, PhD
Senior Research Scientist and Group Leader, Assay Design
Promega Corporation
Dr. Hicham Zegzouti is a Senior Research Scientist in Promega Assay Design-R&D. His group develops biochemical and cell-based assay technologies to interrogate diverse enzyme activities and cellular pathways (kinases, glycosyltransferases, and other drug targets). Dr. Zegzouti received his PhD in 1997 from the National Polytechnic Institute of Toulouse, France.
Prior to joining Promega, he was a postdoctoral researcher in Molecular, Cell and Developmental Biology at UC-Los Angeles studying auxin hormone signaling in an Arabidopsis plant model. His work focused on the identification and characterization of AGC kinase family and its regulation during plant development. Dr. Zegzouti has authored 26 journal articles and book chapters, co-edited a Kinase screening methods book and is an inventor for 3 issued and 2 pending patents.